Abeome Corp., of Athens, Ga., formed a scientific advisory board, led by Richard Meagher, with the appointments of Christine Debouck, Jeff Boyd and Linda Matsuuchi.

Abingdon Life Sciences Inc., of Carlsbad, Calif., appointed Charles H. Davis vice president of regulatory science.

Acrongenomics Inc., of Geneva, appointed Evan Manolis chairman.

Adnexus Therapeutics Inc., of Waltham, Mass., named Sharon Cload vice president of discovery.

Aegerion Pharmaceuticals Inc., of Bridgewater, N.J., appointed Peter L. Garrambone to its board.

Affitech AS, of Oslo, Norway, appointed Keith McCullagh nonexecutive chairman.

Alba Therapeutics Corp., of Baltimore, promoted Linda Arterburn to vice president of preclinical development and program management; Francisco Leon to vice president of clinical development and medical affairs; Roberto Allen to vice president of legal affairs and intellectual property; Mark Ginski to senior director of product and analytical development; and Kate Huber to director of clinical operations.

Alnylam Pharmaceuticals Inc., of Cambridge, Mass., appointed John A. Schmidt chief scientific officer.

AlphaRx Inc., of Markham, Ontario, appointed Donald Low to its scientific advisory board.

Amarin Corp. plc, of Dublin, Ireland, appointed Mehar S. Manku chief scientist and named Paresh Soni senior vice president and head of development.

Amgen Inc., of Thousand Oaks, Calif., appointed Francois de Carbonnel to its board.

Anesiva Inc., of South San Francisco, named William Houghton senior vice president and chief medical officer.

Ariad Pharmaceuticals Inc., of Cambridge, Mass., appointed Maria E. Cantor vice president of corporate communications and investor relations. It also named Massimo Radaelli and Wayne Wilson to its board.

Aruna Biomedical Inc., of Athens, Ga., appointed Harold "Bud" Ingalls to its board.

Avexa Ltd., of Melbourne, Australia, named Nathan Drona chairman and added David Bottomley and Alan Boyd to the board.

Biocept Inc., of San Diego, appointed Stephen M. Coutts CEO, president and director and named Edward A. Dennis director.

BioReliance Corp., of Rockville, Md., named Philip A. Theodore vice president of compliance, legal and corporate development.

BioSpecifics Technologies Corp., of Lynbrook, N.Y., appointed Matthew Geller to its board.

BiPar Sciences Inc., of Brisbane, Calif., named Sunil Patel vice president of corporate development and marketing and appointed Adrienne Weil legal counsel.

BT Pharma, of Toulouse, France, appointed Thierry Hercend president of the supervisory board.

Castle Biosciences, of Houston, appointed Derek Maetzold president and CEO.

Cell Therapeutics Inc., of Seattle, named Christina A. Waters president of CTI Europe.

Cequent Pharmaceuticals, of Cambridge, Mass., named Judy Lieberman and Patrice Courvalin to its scientific advisory board.

Codexis Inc., of Redwood City, Calif., named Lynn Marcus-Wyner vice president of intellectual property.

Concert Pharmaceuticals Inc., of Lexington, Mass., named Steven B. Bernitz senior vice president and chief business officer.

Covalon Technologies Ltd., of Mississauga, Ontario, appointed Peter Hobbes chief financial officer.

Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., appointed Nicholas Bacopoulos to its board.

Cyntellect, of San Diego, appointed David Burns vice president of sales and marketing and chief operating officer.

Cytochroma, of Markham, Ontario, appointed Steven I. Engel vice president of regulatory affairs and quality assurance.

Cytomedix Inc., of Rockville, Md., appointed Peter Anton Clausen vice president of business development.

DOR BioPharma Inc., of Ewing, N.J., formed a European medical advisory board chaired by George B. McDonald, and that also includes Dietger Neiderwieser, Jane Apperley, Andrea Bacigalupo, Jose Antonio Perez Simon and Hans Hagglund.

Enobia Pharma, of Montreal, named Julie Anne Smith vice president and chief commercial officer and appointed Jayant Aphale vice president of manufacturing and process sciences.

Epiphany Biosciences Inc., of San Francisco, named Charles Sanders lead director.

Exosome Diagnostics Inc., of New York, appointed Roger Henriksson to its scientific advisory board. The company also named Wayne D. Comper chief scientific officer. It formed its scientific advisory board with the appointments of Dennis Brown, Xandra Breakefield and Richard L. Edelson, and also appointed Johan Skog director of genetics research.

Frazier Healthcare Ventures, of Seattle, named Bob More general partner.

Genentech Inc., of South San Francisco, appointed Morgan Sheng vice president of neuroscience.

Genome Quest Inc., of Westborough, Mass., named Deirdre O. Aubuchon chief financial officer.

Genstruct Inc., of Cambridge, Mass., appointed Louis Latino vice president of sales.

Gilead Sciences Inc., of Foster City, Calif., named Seigo Isumo senior vice president of cardiovascular therapeutics.

Haemacure Corp., of Montreal, appointed Thomas J. Lynch to its board.

Halozyme Therapeutics Inc., of San Diego, appointed Patrick O'Connor vice president of research and Michael J. LaBarre vice president of product development. It named James E. Cartoni vice president of legal and Douglas B. Muchmore vice president of endocrinology clinical development.